Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
Technology appraisal
Reference number: TA636
Published:
Suspended, the company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.